Antifungal nanofibers made by controlled release of sea animal derived peptide

Nanoscale
Juliane F C VianaOctávio L Franco

Abstract

Candida albicans is a common human-pathogenic fungal species with the ability to cause several diseases including surface infections. Despite the clear difficulties of Candida control, antimicrobial peptides (AMPs) have emerged as an alternative strategy for fungal control. In this report, different concentrations of antifungal Cm-p1 (Cencritchis muricatus peptide 1) were electrospun into nanofibers for drug delivery. The nanofibers were characterized by mass spectrometry confirming the presence of the peptide on the scaffold. Atomic force microscopy and scanning electronic microscopy were used to measure the diameters, showing that Cm-p1 affects fiber morphology as well as the diameter and scaffold thickness. The Cm-p1 release behavior from the nanofibers demonstrated peptide release from 30 min to three days, leading to effective yeast control in the first 24 hours. Moreover, the biocompatibility of the fibers were evaluated through a MTS assay as well as ROS production by using a HUVEC model, showing that the fibers do not affect cell viability and only nanofibers containing 10% Cm-p1-PVA improved ROS generation. In addition, the secretion of pro-inflammatory cytokines IL-6 and TNF-α by the HUVECs was also slightly modified ...Continue Reading

References

Jun 1, 1993·Toxicon : Official Journal of the International Society on Toxinology·G S Bignami
Dec 20, 2003·Cellular and Molecular Life Sciences : CMLS·P W DempseyG Cheng
Jun 30, 2004·Trends in Microbiology·Peter SudberyJudith Berman
Oct 8, 2008·Antimicrobial Agents and Chemotherapy·Hadar SarigAmram Mor
Aug 28, 2010·Journal of Microbiology and Biotechnology·Juneyoung Lee, Dong Gun Lee
Oct 20, 2010·Expert Opinion on Biological Therapy·Satya PrakashArghya Paul
Oct 14, 2011·Frontiers in Microbiology·An M AertsKarin Thevissen
Feb 22, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Anne J MeinelLorenz Meinel
Mar 13, 2012·Journal of Materials Science. Materials in Medicine·Timothy T RuckhKetul C Popat
Apr 20, 2012·Mini Reviews in Medicinal Chemistry·A Brandelli
May 23, 2012·Current Opinion in Microbiology·Neil A R Gow, Bernhard Hube
Sep 15, 2012·Methods in Molecular Biology·Federica TramerSabina Passamonti
Jan 22, 2013·Veterinary Dermatology·Maryam Afshar, Richard L Gallo
Apr 10, 2013·Journal of Biomaterials Science. Polymer Edition·Radhakrishnan SridharSeeram Ramakrishna
Apr 30, 2013·Journal of Biomedical Nanotechnology·T H B EriksenP Fojan
May 3, 2013·Probiotics and Antimicrobial Proteins·Nicolás I TorresMichael L Chikindas
May 25, 2013·Journal of Biomedical Materials Research. Part a·Zhenwei ZouXiaodong Guo
May 30, 2013·Virulence·Anna C B P CostaAntonio O C Jorge
Jun 5, 2013·Antimicrobial Agents and Chemotherapy·Tiaan D J HeunisLeon M T Dicks
Jun 26, 2013·Journal of Biomaterials Science. Polymer Edition·Rachna DaveVayalam P Venugopalan
Jul 11, 2013·Frontiers in Immunology·Allen J Duplantier, Monique L van Hoek
Aug 27, 2013·Acta Biomaterialia·Anwarul HasanAli Khademhosseini
Nov 6, 2013·Carbohydrate Polymers·Abdelrahman M AbdelgawadOrlando J Rojas
Dec 19, 2013·The Journal of Biological Chemistry·Jason Koontz, Aikaterini Kontrogianni-Konstantopoulos
Jan 1, 2014·Journal of Biomedical Materials Research. Part a·Ibrahim Anwar HassounahRoop L Mahajan
Feb 12, 2014·Advanced Biomedical Research·Patricia Méndez-Samperio
Feb 20, 2014·Peptides·Elizabete de Souza CândidoOctávio Luiz Franco
May 6, 2014·JAMA : the Journal of the American Medical Association·Daniel K BenjaminUNKNOWN Fluconazole Prophylaxis Study Team
Jul 26, 2014·Mediators of Inflammation·Adriano Fernando AraújoMauricio Martins Rodrigues

❮ Previous
Next ❯

Citations

Jan 21, 2016·Expert Opinion on Drug Delivery·Lan MeiGang Guo
Aug 10, 2016·Future Medicinal Chemistry·Tecla CiociolaLuciano Polonelli
Nov 13, 2018·Expert Opinion on Drug Delivery·James R SmithDimitrios A Lamprou
Jul 25, 2019·Macromolecular Bioscience·Alexander DartPeter Kingshott
May 14, 2020·Expert Opinion on Drug Delivery·Maurício G C SousaOctávio L Franco
Oct 4, 2017·Frontiers in Chemistry·Martijn RioolSebastian A J Zaat
Mar 30, 2016·Materials·Ji Wang, Wilfred Vermerris
Nov 21, 2018·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Wenqiang LiChangren Zhou
Mar 21, 2021·Drug Discovery Today·Maurício G C SousaOctávio L Franco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.